The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

The Globe and Mail has
updated our Stock Quote Pages
You are about to experience the newly designed Stock Quote Pages format. With the new layout, you'll enjoy a more in-depth look at the companies you're following and pages that are easier to navigate. This Editors' blog post explains why we've made these changes.

 

Abbott Laboratories

NYSE: ABT
Last

(U.S.) $46.05

Today's change+0.28 +0.61%
Updated December 19 4:01 PM EST. Delayed by at least 15 minutes.
 

Abbott Laboratories

NYSE: ABT
Last

(U.S.) $46.05

Today's change+0.28 +0.61%
Updated December 19 4:01 PM EST. Delayed by at least 15 minutes.

Abbott Laboratories Hits New 52-week High

Abbott Laboratories closed up Friday by (U.S.)$0.28 or 0.61% to (U.S.)$46.05 and setting a new 52-week high. Over the last five days, shares have gained 5.40% and 20.14% year to date. Shares have outperformed the S&P 500 by 6.66% during the last year.

Key company metrics

  • Open(U.S.) $45.91
  • Previous close(U.S.) $45.77
  • High(U.S.) $46.45
  • Low(U.S.) $45.78
  • Bid / Ask-- / --
  • YTD % change+20.14%
  • Volume11,329,197
  • Average volume (10-day)5,667,984
  • Average volume (1-month)5,336,967
  • Average volume (3-month)5,228,490
  • 52-week range(U.S.) $35.65 to (U.S.) $46.45
  • Beta0.61
  • Trailing P/E42.19×
  • P/E 1 year forward20.35×
  • Forward PEG2.12×
  • Indicated annual dividend(U.S.) $0.96
  • Dividend yield2.08%
  • Trailing EPS(U.S.) $1.09
Updated December 19 4:01 PM EST. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+8.14%

Based on its net profit margin of 8.14%, Abbott Laboratories is less effective than other companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.85%Sector:HealthcareIndustry:Pharmaceuticals - Diversified
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q3/2014Q2/2014Q1/2014Q4/2013
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedSep 30, 201409/30/2014Jun 30, 201406/30/2014Mar 31, 201403/31/2014Dec 31, 201312/31/2013
Revenue5,1045,5515,2445,655
Total other revenue--------
Total revenue5,1045,5515,2445,655
Gross profit2,7783,0482,7793,095
Total cost of revenue2,3262,5032,4652,560
Total operating expense4,3734,7904,7934,899
Selling / general / administrative1,5661,7371,7391,654
Research & development305335387386
Depreciation / amortization132161174198
Interest expense (income), net operating--------
Unusual expense (income)44512582
Other operating expenses, total--------
Operating income731761451756
Interest income (expense), net non-operating-35---49--
Gain (loss) on sale of assets--------
Other--------
Income before tax718737423737
Income after tax440460339589
Income tax, total27827784148
Net income538466375590
Total adjustments to net income--------
Net income before extra. items440460339589
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items440460339589
Inc. avail. to common incl. extra. items538466375590
Diluted net income538466375590
Dilution adjustment--0----
Diluted weighted average shares1,5201,5171,5481,567
Diluted EPS excluding extraordinary itemsvalue per share0.290.300.220.38
Dividends per sharevalue per share0.220.220.220.14
Diluted normalized EPSvalue per share0.310.320.230.42